Tim Hoey

Tim Hoey

Company: Tenaya Therapeutics

Job title: Chief Scientific Officer

Seminars:

Development of TN-301 – A Highly Selective HDAC6 Inhibitor for HFpEF Treatment 8:30 am

• Explore the discovery of HDAC6 as a novel target for heart failure through a high content screening approach in iPS-derived cardiomyocytes • Hear how TN-301 has activity in in vivo HFpEF models and works through multiple mechanisms of action including blocking fibrosis, inflammation, and modulating metabolic pathways • Learn about IND-enabling studies that are…Read more

day: Day One

Moderated Discussion – Understanding HFpEF 10:00 am

Are we able to define the HFpEF patient? Is HFpEF heterogeneous or is our understanding incomplete? Is there a unifying hypothesis?Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.